Finally, it is worth noting that besides the AURKA/B pathways genes, the remaining 118 genes that are repressed by the p53-RBL2-DREAM pathway may also be important for therapy responsiveness and outcome in NSCLC. This evidence concerns the gene TP53 and non-small cell lung carcinoma.